Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.20)
# 2,528
Out of 4,829 analysts
204
Total ratings
35.65%
Success rate
-3.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $64 → $65 | $35.11 | +85.13% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $183 → $166 | $97.78 | +69.77% | 6 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $8.34 | +103.84% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $2.96 | +1,048.65% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $57.38 | +25.48% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $44.23 | +58.26% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $115.71 | +29.63% | 26 | Mar 7, 2025 | |
| ERAS Erasca | Assumes: Overweight | $4 | $1.38 | +189.86% | 3 | Mar 7, 2025 | |
| IRON Disc Medicine | Assumes: Overweight | $85 | $44.24 | +92.13% | 6 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Assumes: Overweight | $38 → $35 | $7.54 | +364.19% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $25 | $3.87 | +545.99% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $55 | $23.74 | +131.68% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $12.30 | +119.51% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.03 | +24.07% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $20 | $17.44 | +14.68% | 24 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $31.70 | +111.39% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $5.99 | +100.50% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.49 | +312.25% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $30.68 | +128.16% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.80 | +398.69% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $2.46 | +62.60% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.65 | +519.10% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $3.50 | +3,900.00% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $1.14 | +1,128.07% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.27 | +293.70% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $0.80 | +275.85% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.35 | +937.04% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.67 | +498.80% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $36.17 | -39.18% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $20.24 | +633.70% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.60 | +3,650.00% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.17 | +89.27% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.45 | +12,007.62% | 6 | May 8, 2020 |
Ultragenyx Pharmaceutical
May 9, 2025
Maintains: Overweight
Price Target: $64 → $65
Current: $35.11
Upside: +85.13%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Overweight
Price Target: $183 → $166
Current: $97.78
Upside: +69.77%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $8.34
Upside: +103.84%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $2.96
Upside: +1,048.65%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $57.38
Upside: +25.48%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $44.23
Upside: +58.26%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $115.71
Upside: +29.63%
Erasca
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.38
Upside: +189.86%
Disc Medicine
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $44.24
Upside: +92.13%
Cullinan Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.54
Upside: +364.19%
Mar 7, 2025
Assumes: Overweight
Price Target: $25
Current: $3.87
Upside: +545.99%
Mar 7, 2025
Assumes: Overweight
Price Target: $55
Current: $23.74
Upside: +131.68%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $12.30
Upside: +119.51%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.03
Upside: +24.07%
Mar 7, 2025
Assumes: Equal-Weight
Price Target: $20
Current: $17.44
Upside: +14.68%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $31.70
Upside: +111.39%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $5.99
Upside: +100.50%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.49
Upside: +312.25%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $30.68
Upside: +128.16%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.80
Upside: +398.69%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $2.46
Upside: +62.60%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.65
Upside: +519.10%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $3.50
Upside: +3,900.00%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.14
Upside: +1,128.07%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.27
Upside: +293.70%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $0.80
Upside: +275.85%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.35
Upside: +937.04%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.67
Upside: +498.80%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $36.17
Upside: -39.18%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $20.24
Upside: +633.70%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.60
Upside: +3,650.00%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.17
Upside: +89.27%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.45
Upside: +12,007.62%